Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
F 17.45 -1.63% -0.29
GH closed down 1.63 percent on Monday, March 18, 2024, on 1.26 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -1.63%
New 52 Week Closing Low Bearish -1.63%
New 52 Week Low Weakness -1.63%
Wide Bands Range Expansion -1.63%
Oversold Stochastic Weakness -1.63%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 14 hours ago
Fell Below Previous Day's Low about 19 hours ago
Down 1% about 19 hours ago
New 52 Week Low about 19 hours ago
Up 1% about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Guardant Health, Inc. Description

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biopharmaceutical Cancer Disease Clinical Development Oncology Telehealth Telemedicine Lab Testing Precision Medicine Blood Test Biopsy Healthcare Costs

Is GH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 41.06
52 Week Low 17.395
Average Volume 1,710,004
200-Day Moving Average 28.86
50-Day Moving Average 21.73
20-Day Moving Average 19.47
10-Day Moving Average 18.70
Average True Range 1.09
RSI (14) 32.43
ADX 32.81
+DI 11.76
-DI 26.60
Chandelier Exit (Long, 3 ATRs) 19.60
Chandelier Exit (Short, 3 ATRs) 20.66
Upper Bollinger Bands 22.38
Lower Bollinger Band 16.57
Percent B (%b) 0.15
BandWidth 29.85
MACD Line -1.11
MACD Signal Line -1.07
MACD Histogram -0.043
Fundamentals Value
Market Cap 2.12 Billion
Num Shares 121 Million
EPS -4.03
Price-to-Earnings (P/E) Ratio -4.33
Price-to-Sales 5.12
Price-to-Book 12.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.31
Resistance 3 (R3) 18.39 18.18 18.17
Resistance 2 (R2) 18.18 17.96 18.14 18.12
Resistance 1 (R1) 17.82 17.82 17.71 17.74 18.07
Pivot Point 17.61 17.61 17.55 17.57 17.61
Support 1 (S1) 17.24 17.39 17.14 17.16 16.83
Support 2 (S2) 17.03 17.25 16.99 16.78
Support 3 (S3) 16.67 17.03 16.73
Support 4 (S4) 16.59